Amivantamab/hyaluronidase

Amivantamab/hyaluronidase, marketed as Rybrevant Faspro, is a fixed-dose combination medication for non-small cell lung cancer. It pairs amivantamab, a bispecific antibody that targets the EGFR and MET receptors involved in tumor growth, with hyaluronidase, an enzyme that breaks down tissue barriers to allow the antibody to be absorbed after a subcutaneous injection rather than an intravenous infusion. It is indicated for advanced non-small cell lung cancer carrying specific EGFR mutations, including exon 19 deletions, the exon 21 L858R substitution, or exon 20 insertions, either as a first treatment or after an earlier treatment has failed. The subcutaneous formulation causes fewer administration reactions than the original intravenous version of amivantamab. It was approved for medical use in the United States in December 2025.